Skip to main content
. 2019 Apr 1;216(5):1199–1213. doi: 10.1084/jem.20181329

Figure 4.

Figure 4.

DNA damage and down-regulation of TREX1 enhance ISG expression in BLM-deficient cells. (A) Protein levels of BLM, TREX1, MX1, IFIT1, and Actin in SV40-immortalized cells after transduction with CRISPR-Cas9 lentivector targeting BLM (sgBLM) and/or TREX1 (sgTREX1) or corresponding control lentivectors (–; representative of n = 5 experiments). (B) mRNA level expression of IFI44L, IFIT1, ISG20, MX1, and OAS1 determined by RT-qPCR in cells, as in A (mean with SD of n = 5 independent experiments; two-way ANOVA with Tukey post-test, *P < 0.05, **P < 0.01, ***P < 0.001). (C) Protein levels of BLM, MX1, IFIT1, and Actin in SV40-immortalized control cells (EV) and BLM-deficient cells (sgBLM) treated with 0.4 µM of aphidicolin for 24 h (representative of n = 5 independent experiments). (D) mRNA level expression of BLM, IFI44L, IFIT1, ISG20, MX1, and OAS1 determined by RT-qPCR in cells, as in C (mean with SD of n = 5 independent experiments; two-way ANOVA with Tukey post-test, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). (E) Protein levels of BLM, MX1, IFIT1, and Actin in SV40-immortalized control cells (EV) and BLM-deficient cells (sgBLM) treated with 0.5 µM of hydroxyurea for 24 h (representative of n = 3 independent experiments). (F) mRNA level expression of BLM, IFI44L, IFIT1, ISG20, MX1, and OAS1 determined by RT-qPCR in cells, as in E (mean with SD of n = 3 independent experiments; one-way ANOVA with Tukey post-test, *P < 0.05, **P < 0.01, ****P < 0.0001).